Anti-inflammatory and antiviral effects of Glossogyne tenuifolia

Immunomodulatory effect of Glossogyne tenuifolia in murine peritoneal macrophages and splenocytes

“…Murine splenocytes have been used as an alternative to human lymphocytes for immunological studies (Cerqueira et al, 2003;Cordeiro-da-Silva et al, 2004). Our current results demonstrates that, unlike in human blood cells where luteolin is the only component responsible for the inhibitory effect of Glossogyne tenuifolia on PHA-activated IFN-␥ release (Wu et al, 2005a), both luteolin-7-glucoside and luteolin are able to attenuate IFN-␥ release in PHA-stimulated murine splenocytes.…”

“…However, it was later discovered that only luteolin, the aglycone of luteolin-7-glucoside, was potent in inhibiting the production of both TNF-␣ and IL-6 in LPS-activated human whole blood and peripheral blood mononuclear cells (PBMC). This would indicate that the anti-inflammatory potencies of natural components are greatly system-dependent (Wu et al, 2005a).…”

“…It has been found that the antioxidant activity of Glossogyne tenuifolia in vitro and in human primary cells may be attributed to flavonoid compounds, but not to oleanolic acid (Hsu et al, 2005;Wu et al, 2005b). In addition, none of the identified compounds were responsible for the inhibitory activities of Glossogyne tenuifolia on hepatitis B surface antigen release (Wu et al, 2005a) or cancer cell line proliferation (Hsu et al, 2005).…”

Cluster Analysis and QSAR Study of Some Anti‐hepatitis B Virus Agents Comprising 4‐Aryl‐6‐chloro‐quinolin‐2‐ones and 5‐Aryl‐7‐chloro‐1,4‐benzodiazepines

“…2 HBV is a fatal disease epidemic in Southeast Asia, Africa and China, where approximately 10% of the populations are chronic carriers. 3 People infected with HBV are at risk of chronic hepatitis, liver failure, cirrhosis, and hepatocellular carcinoma leading to significant mortality and serious long-term morbidity, [4][5][6] which are 10 times more numerous than HIV (human immunodeficiency virus) patients. 7 No effective therapy against HBV infection has been fully developed so far 8,9 and the molecular mechanisms of HBV-mediated hepatocarcinogenesis are still poorly understood.…”

“…16,17 The unsatisfactory therapeutic application of current anti-viral drugs has strengthened the urgent demand for novel anti-HBV agents to circumvent the existing therapeutic difficulties. 3,15,17 Computational chemistry has developed into an important contributor to rational drug design. The quanti-tative structure-activity relationship (QSAR) approach pioneered by Hansch and co-workers 18 is a useful tool in correlating the specific biological activity with molecular structural properties of the compounds, which has been proved to be one of the most embraced computational approaches in modern drug discovery.…”